Hemorrhage clinical trials at University of California Health

5 in progress, 3 open to eligible people

Showing trials for

  • CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

    open to eligible people ages 18-90

    The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.

    at UCSF

  • Onyx™ Liquid Embolic IDE Clinical Study

    open to eligible people ages 22 years and up

    The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.

    at UC Irvine

  • Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

    open to eligible females ages 18 years and up

    Although procedural abortion in the second trimester is extremely safe, hemorrhage is one of the leading causes of morbidity and mortality. Tranexamic acid (TXA) is used commonly in obstetrics to prevent or manage intrapartum or postpartum hemorrhage and has been associated with decreased mortality and decreased blood loss at the time of birth. Some guidelines are recommending the use of TXA for both the prevention and management of bleeding for abortion care. However, there are currently no published studies assessing the association between TXA and bleeding outcomes for abortion procedures. This study will involve a randomized, placebo-controlled trial of pregnant patients aged 18 and older desiring dilation and evacuation (D&E) for abortion or fetal demise at 18-24 weeks gestation. The primary aim is to determine whether prophylactic TXA has an effect on the need for additional interventions to control bleeding at the time of D&E. The secondary aim is to determine whether prophylactic TXA has an effect on the mean quantitative procedural blood loss.

    at UCSD

  • Empiric Calcium in Massive Transfusion

    Sorry, not yet accepting patients

    Calcium helps blood to clot and thereby stop bleeding. Trauma patients who experience large volume blood loss often require blood transfusions and bleeding is the most common cause of death. The purpose of this study is to see if giving intravenous calcium immediately to patients who require large volume blood transfusion will decrease transfusion requirements, vasopressor use and mortality in bleeding trauma patients.

    at UC Irvine

  • Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: an Efficacy Study

    Sorry, not yet accepting patients

    Trauma is the leading cause of death and disability in children in the United States. The objective of this study is to evaluate the benefits and harms of tranexamic acid (TXA; a drug that stops bleeding) in severely injured children with hemorrhagic brain and/or torso injuries. Using thromboelastography, we will measure baseline fibrinolysis to assess for treatment effects of TXA at different levels of fibrinolysis.

    at UC Davis

Our lead scientists for Hemorrhage research studies include .

Last updated: